About dabigatran etexilate
Direct thrombin inhibitor anticoagulant
Used for
- Prevention of stroke and blood clots in nonvalvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis and pulmonary embolism
- Prevention of blood clots after hip replacement surgery
Usual adult dose
Atrial fibrillation: commonly 150 mg twice daily; 110 mg twice daily may be used in selected patients. DVT/PE treatment: 150 mg twice daily after initial injectable anticoagulation.
Usual dose in children
For children aged 8 years and older, dosing is weight-based and depends on the indication and formulation.
Common side effects
- Bleeding or bruising
- Indigestion or stomach pain
- Nausea
- Anemia
Important warnings
- Serious or fatal bleeding can occur.
- Stopping suddenly may increase stroke or clot risk.
- Kidney function affects dosing and suitability.
- Capsules must be swallowed whole; do not open or crush.
Pregnancy
Use is generally avoided during pregnancy because of bleeding risk and limited safety information.
Breastfeeding
Breastfeeding is generally not recommended during treatment; safety information is limited.
Interactions
- Other anticoagulants and antiplatelet medicines increase bleeding risk.
- NSAIDs such as ibuprofen increase bleeding risk.
- P-glycoprotein inhibitors, including ketoconazole, can raise dabigatran levels.
- Rifampin can lower dabigatran levels.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.